TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.

Palit, Sander Al; Vis, Daniel; Stelloo, Suzan; Lieftink, Cor; Prekovic, Stefan; Bekers, Elise; Hofland, Ingrid; Sustic, Tonci; Wolters, Liesanne; Beijersbergen, Roderick; Bergman, Andries M; Gyorffy, Balázs; Wessels, Lodewyk Fa; Zwart, Wilbert; van der Heijden, Michiel S

Palit, Sander Al; Vis, Daniel; Stelloo, Suzan; Lieftink, Cor; Prekovic, Stefan; Bekers, Elise; Hofland, Ingrid; Sustic, Tonci; Wolters, Liesanne; Beijersbergen, Roderick; Bergman, Andries M; Gyorffy, Balázs; Wessels, Lodewyk Fa; Zwart, Wilbert; van der Heijden, Michiel S.

Afiliação

Palit SA; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Vis D; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Stelloo S; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
Lieftink C; Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
Prekovic S; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Bekers E; Division of Oncogenomics, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
Hofland I; Division of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Sustic T; Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands.
Wolters L; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Beijersbergen R; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, Netherlands.
Bergman AM; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Gyorffy B; Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands.
Wessels LF; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Zwart W; Department of Bioinformatics, Semmelweis University, Budapest, Hungary.
van der Heijden MS; TTK Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary.

Elife ; 82019 12 19.

Article em En | MEDLINE | ID: mdl-31855178

Assuntos

Proteínas Correpressoras/genética; Fator 3-alfa Nuclear de Hepatócito/genética; Neoplasias da Próstata/genética; Receptores Androgênicos/genética; Antagonistas de Receptores de Andrógenos/farmacologia; Benzamidas; Sistemas CRISPR-Cas/genética; Linhagem Celular Tumoral; Proliferação de Células/efeitos dos fármacos; Resistencia a Medicamentos Antineoplásicos/genética; Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos; Células HEK293; Humanos; Masculino; Nitrilas; Feniltioidantoína/análogos & derivados; Feniltioidantoína/farmacologia; Próstata/metabolismo; Neoplasias da Próstata/tratamento farmacológico; Neoplasias da Próstata/patologia; Receptores de Glucocorticoides/genética; Ativação Transcricional/efeitos dos fármacos

Palavras-chave

Enzalutamide; TLE3; androgen receptor; cancer biology; glucocorticoid receptor; human; prostate cancer; therapy resistance

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Receptores Androgênicos / Fator 3-alfa Nuclear de Hepatócito / Proteínas Correpressoras Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google